Gadovist Gadobutrol Injection

1. Indications and Usage
Gadobutrol injection is indicated for intravascular use in the diagnosis of various lesions by contrast-enhanced magnetic resonance imaging (CE-MRI) of the whole body, including the brain and spine, and contrast-enhanced magnetic resonance angiography (CE-MRA) of the whole body.
2. Dosage and Administration
Recommended Dosage: The recommended dose for adults for CE-MRI of the brain and spine is 0.1 mmol/kg (0.1 mL/kg of the 1.0 M solution).
CE-MRA Dosage: For CE-MRA involving one or multiple fields of view, the dose typically ranges from 0.1 to 0.3 mmol/kg depending on patient weight and the number of views.
Administration: The injection should be administered as a rapid intravenous bolus. For CE-MRI, optimal imaging is usually observed within 15 minutes post-injection.
Repeat Dosage: If the initial scan is inconclusive, an additional dose of up to 0.2 mmol/kg may be administered within 30 minutes of the first dose.
3. Mechanism of Action
Gadobutrol contains paramagnetic gadolinium ions. In an external magnetic field, these ions alter the relaxation times of nearby hydrogen protons, thereby increasing the signal intensity on T1-weighted MRI images and enhancing the visibility of vascularized tissues and pathological lesions.
4. Safety and Warnings
Nephrogenic Systemic Fibrosis (NSF): Gadolinium-based contrast agents pose a risk of NSF in patients with acute or severe chronic renal impairment (GFR <30 mL/min/1.73 m²).
Hypersensitivity: Serious and rare hypersensitivity reactions, including anaphylaxis, may occur. Life-support equipment should be readily available during administration.
Gadolinium Retention: Trace amounts of gadolinium have been found to persist in the brain and other tissues, although the clinical significance is currently unknown.
Seizures: Seizures have been reported, particularly when the blood-brain barrier is compromised.
5. Adverse Reactions and Clinical Research
Common Adverse Reactions: The most frequently reported adverse reactions include headache, dizziness, nausea, injection site reactions, dysgeusia, and sensation of warmth.
Clinical Research: Pivotal clinical trials have demonstrated high efficacy and safety in enhancing diagnostic confidence for various intracranial, spinal, and systemic pathologies.
6. Drug Interactions
General: No formal pharmacokinetic drug interaction studies have been conducted.
Drugs Affecting QT Interval: Gadobutrol may theoretically increase the QT-interval prolonging effects of other drugs (e.g., cisapride, erythromycin, antipsychotics).
7. Pharmaceutical Information
Composition: The active ingredient is gadobutrol, a gadolinium chelate.
Appearance: A clear, colorless to pale yellow liquid for intravenous use.
Storage: Store in a tight container and protect from light. The solution should be inspected visually for particulate matter and discoloration prior to administration.